[{"orgOrder":0,"company":"Crossject","sponsor":"AFT Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"FRANCE","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Midazolam","moa":"GABAA receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Crossject","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Crossject \/ AFT Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Crossject \/ AFT Pharmaceuticals"},{"orgOrder":0,"company":"Crossject","sponsor":"Bpifrance","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"FRANCE","productType":"Other Small Molecule","year":"2024","type":"Financing","leadProduct":"Midazolam","moa":"GABAA receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Crossject","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Crossject \/ Bpifrance","highestDevelopmentStatusID":"15","companyTruncated":"Crossject \/ Bpifrance"},{"orgOrder":0,"company":"Crossject","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"FRANCE","productType":"Other Small Molecule","year":"2023","type":"Agreement","leadProduct":"Midazolam","moa":"GABAA receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Crossject","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Crossject \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Crossject \/ Undisclosed"},{"orgOrder":0,"company":"Crossject","sponsor":"Gemmes Venture","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"FRANCE","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"Midazolam","moa":"GABAA receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Crossject","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Crossject \/ Gemmes Venture","highestDevelopmentStatusID":"15","companyTruncated":"Crossject \/ Gemmes Venture"},{"orgOrder":0,"company":"Crossject","sponsor":"Heights Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"FRANCE","productType":"Other Small Molecule","year":"2024","type":"Financing","leadProduct":"Midazolam","moa":"GABAA receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Crossject","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Crossject \/ Heights Capital Management","highestDevelopmentStatusID":"15","companyTruncated":"Crossject \/ Heights Capital Management"},{"orgOrder":0,"company":"Crossject","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"FRANCE","productType":"Other Small Molecule","year":"2024","type":"Agreement","leadProduct":"Midazolam","moa":"GABAA receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Crossject","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Crossject \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Crossject \/ Undisclosed"},{"orgOrder":0,"company":"Crossject","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Agreement","leadProduct":"Midazolam","moa":"GABAA receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Crossject","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Crossject \/ BARDA","highestDevelopmentStatusID":"15","companyTruncated":"Crossject \/ BARDA"},{"orgOrder":0,"company":"Crossject","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Midazolam","moa":"GABAA receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Crossject","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Crossject \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Crossject \/ Inapplicable"},{"orgOrder":0,"company":"Crossject","sponsor":"Eton Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"FRANCE","productType":"Steroid","year":"2025","type":"Collaboration","leadProduct":"Hydrocortisone","moa":"Glucocorticoid receptor","graph1":"Neurology","graph2":"Undisclosed","graph3":"Crossject","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Crossject \/ Eton Pharmaceuticals","highestDevelopmentStatusID":"1","companyTruncated":"Crossject \/ Eton Pharmaceuticals"}]

Find Clinical Drug Pipeline Developments & Deals by Crossject

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Cophex
                          Not Confirmed
                          Cophex
                          Not Confirmed

                          Details : ETON in-licensed commercialization rights to ZENEO® Hydrocortisone, a unique, and proprietary ready-to-use liquid formulation of hydrocortisone, for the US and Canadian markets.

                          Product Name : Zeneo

                          Product Type : Steroid

                          Upfront Cash : Undisclosed

                          March 25, 2025

                          Lead Product(s) : Hydrocortisone

                          Therapeutic Area : Neurology

                          Highest Development Status : Undisclosed

                          Sponsor : Eton Pharmaceuticals

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          02

                          Cophex
                          Not Confirmed
                          Cophex
                          Not Confirmed

                          Details : The proceeds will support development of crossject's ZENEO® Epinephrine needle-free autoinjector, for treatment of severe allergic reactions (anaphylactic shock).

                          Product Name : Zepizure

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          October 07, 2024

                          Lead Product(s) : Midazolam

                          Therapeutic Area : Neurology

                          Highest Development Status : Approved FDF

                          Sponsor : Bpifrance

                          Deal Size : $7.4 million

                          Deal Type : Financing

                          blank

                          03

                          Cophex
                          Not Confirmed
                          Cophex
                          Not Confirmed

                          Details : The net proceeds will be used to support Crossject’s activities in bringing its Zepizure (midazolam), a short-acting hypnotic-sedative epileptic rescue therapy, to market.

                          Product Name : Zepizure

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          April 06, 2024

                          Lead Product(s) : Midazolam

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase I

                          Sponsor : Gemmes Venture

                          Deal Size : $8.2 million

                          Deal Type : Public Offering

                          blank

                          04

                          Cophex
                          Not Confirmed
                          Cophex
                          Not Confirmed

                          Details : The financing aims to support the clinical development of Zepizure (midazolam), a short-acting hypnotic-sedative medication currently undergoing evaluation in patients for epileptic seizures.

                          Product Name : Zepizure

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          February 27, 2024

                          Lead Product(s) : Midazolam

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase I

                          Sponsor : Heights Capital Management

                          Deal Size : $12.0 million

                          Deal Type : Financing

                          blank

                          05

                          Cophex
                          Not Confirmed
                          Cophex
                          Not Confirmed

                          Details : Under the terms of the agreement, Crossject Zepizure (midazolam) will be commercialized in the European market for the treatment of epileptic seizures.

                          Product Name : Zepizure

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          February 05, 2024

                          Lead Product(s) : Midazolam

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase I

                          Sponsor : Undisclosed

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank

                          06

                          Cophex
                          Not Confirmed
                          Cophex
                          Not Confirmed

                          Details : The agreement aims for the commercialization of Crossject's innovative rescue therapy for epileptic seizures Zepizure (midazolam), previously known as ZENEO® Midazolam, in northern Europe covering Germany, the UK, Denmark, Sweden, Finland and Norway.

                          Product Name : Zepizure

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          December 22, 2023

                          Lead Product(s) : Midazolam

                          Therapeutic Area : Neurology

                          Highest Development Status : Approved FDF

                          Sponsor : Undisclosed

                          Deal Size : $1.0 million

                          Deal Type : Agreement

                          blank

                          07

                          MAGHREB PHARMA
                          Not Confirmed
                          MAGHREB PHARMA
                          Not Confirmed

                          Details : Under the agreement, AFT will commercialise ZENEO® Midazolam, a combination of the single use needle-free auto injector ZENEO® and the drug product midazolam, in epileptic seizures in Australia and New Zealand.

                          Product Name : Zepizure

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          July 20, 2023

                          Lead Product(s) : Midazolam

                          Therapeutic Area : Neurology

                          Highest Development Status : Approved FDF

                          Sponsor : AFT Pharmaceuticals

                          Deal Size : $0.7 million

                          Deal Type : Licensing Agreement

                          blank

                          08

                          Cophex
                          Not Confirmed
                          Cophex
                          Not Confirmed

                          Details : ZENEO's Midazolam is developed as a combination of the single use needle-free auto injector ZENEO and the drug product midazolam, which is an improved anti-convulsant benzodiazepine recommended for treatment of strong seizures resulting from epilepsia.

                          Product Name : Zepizure

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          June 18, 2022

                          Lead Product(s) : Midazolam

                          Therapeutic Area : Neurology

                          Highest Development Status : Approved FDF

                          Sponsor : BARDA

                          Deal Size : $60.0 million

                          Deal Type : Agreement

                          blank

                          09

                          Cophex
                          Not Confirmed
                          Cophex
                          Not Confirmed

                          Details : ZENEO and the syringe with intramucular needle showed a similar and low inter-subject variability of midazolam pharmacokinetics. This is an additional demonstration that an injection with ZENEO reached muscle in the same way as an injection with a syring...

                          Product Name : Zepizure

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          February 11, 2022

                          Lead Product(s) : Midazolam

                          Therapeutic Area : Neurology

                          Highest Development Status : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank